Ally Bridge Group NY LLC and Ensign Peak Advisors Inc. made significant new investments in Tyra Biosciences, with stakes worth approximately $4.23 million and $3.05 million, respectively. American Century Companies Inc. increased its stake by 582.9%, now holding 170,283 shares valued at $2.72 million. The company, focused on precision medicines for FGFR biology, has a consensus "Buy" rating from analysts, with a target price averaging $30.50, despite recent earnings missing expectations.